In early June, an announcement from the US Food and Drug Administration highlighted an urgent need to secure continued supplies of certain drugs. The agency noted that more than 130 products, including 14 treatments for cancer, were in short supply.
China Steps In To Help Relieve US Cancer Drug Shortages
Despite Wider Decoupling Underway
At least one major Chinese supplier is being tapped to relieve a shortage of certain drugs in the US despite rising Beijing-Washington tensions, but China may be increasingly unwilling to co-operate amid its own shifting economic priorities, increasingly introspective policies and some shortages of its own.
More from China
More from Focus On Asia
• By
AstraZeneca logs growth in Japan despite a big reimbursement price cut for one of its top sellers and expects 40 approvals in the country over the next six years.
• By
GNT Pharma prepares for the first listing of a Korean biotech on Nasdaq, while others sign major global out-licensing deals with large multinational partners.
• By
India and the US are the major manufacturers of finished dosages for the US market in terms of volume (China accounts for 9% of injectables), though the US relies heavily on India for solid oral dosage forms and specific generics, including lenalidomide and albuterol. Scrip talks to experts on some of the key implications of geographic concentration of production for the US market amid the specter of tariffs.